{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-009590","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2024-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.319043+00:00","generated_at":"2026-06-04T07:31:47.043330+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioCardia FY2023 net loss $11.6M; CardiAMP HF trial misses primary endpoint but subgroup shows benefit","bullets":["Revenue $0.5M (down from $1.4M); net loss $11.6M; cash $1.1M at year-end; financing provides runway into Q2 2024.","CardiAMP HF trial missed primary endpoint; interim data: 37% RR reduction in heart death equivalents overall.","In NTproBNP-elevated subgroup (59% of patients): 86.2% RR reduction in heart death equivalents (2.9% vs 21.1%).","Confirmatory Phase III CardiAMP HF II trial approved by FDA with >90% power; Medicare reimbursement certified.","Morph DNA steerable sheath family expects FDA approval Q3 2024; two additional biotherapeutic delivery partnerships anticipated."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-009590","json":"https://secwatch.observer/filing/0001437749-24-009590.json","markdown":"https://secwatch.observer/filing/0001437749-24-009590.md","text":"https://secwatch.observer/filing/0001437749-24-009590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/0001437749-24-009590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/bcda20240326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:31:47.043330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9b54c72d8a76e4665faa862ac04ab0f40023ca0","claim":"BioCardia, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 27, 2024, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774924009590/0001437749-24-009590-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}